Stock listing
NASDAQ:TYRA Tyra Biosciences, Inc. Stock
Home listing (NASDAQ) of Tyra Biosciences, Inc.
Follow Tyra Biosciences, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:TYRA
$20.12 USD +0.51 (+2.6%)
Close on Nov 20, 2026
- Day range
- $19.48 – $20.44 USDNov 20, 2026
- Volume
- 467,578 sharesNov 20, 2026
- Market cap
- $1.39B USDAt the close on Nov 20, 2026 · price × 69.08M shares outstanding
- 52-week range
- $18.25 – $40.65 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $19.11M USDMedian day 648,973 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:TYRA · Home | $20.12 USD | +0.51 (+2.6%) | 467,578 | $19.62 | $20.44 | $19.48 | $19.61 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:TYRA · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $20.12 | +0.51 | +2.6% | $19.62 | $20.44 | $19.48 | 467,578 | |
| $19.61 | +0.04 | +0.2% | $19.50 | $20.27 | $19.26 | 472,171 | |
| $19.57 | -0.17 | -0.9% | $20.17 | $20.79 | $19.34 | 690,592 | |
| $19.74 | -0.285 | -1.4% | $20.03 | $20.61 | $19.60 | 803,180 | |
| $20.03 | +0.26 | +1.3% | $19.99 | $20.12 | $19.27 | 375,083 | |
| $19.77 | -1.205 | -5.7% | $20.67 | $21.43 | $19.66 | 857,073 | |
| $20.97 | -0.03 | -0.1% | $20.98 | $21.39 | $20.72 | 532,706 | |
| $21.00 | -1.30 | -5.8% | $22.00 | $22.58 | $20.80 | 793,825 | |
| $22.30 | +1.15 | +5.4% | $21.35 | $23.00 | $20.89 | 343,151 | |
| $21.15 | +0.26 | +1.2% | $21.22 | $21.59 | $20.75 | 862,264 | |
| $20.89 | -0.635 | -3.0% | $21.54 | $21.65 | $20.79 | 694,655 | |
| $21.53 | +0.155 | +0.7% | $21.91 | $21.91 | $20.78 | 542,625 | |
| $21.37 | +0.04 | +0.2% | $21.50 | $21.94 | $21.23 | 433,755 | |
| $21.33 | +0.26 | +1.2% | $21.08 | $21.62 | $20.75 | 539,379 | |
| $21.07 | -0.41 | -1.9% | $21.18 | $21.55 | $20.32 | 625,768 | |
| $21.48 | -0.27 | -1.2% | $21.92 | $22.37 | $21.10 | 734,901 | |
| $21.75 | +0.23 | +1.1% | $21.31 | $21.79 | $21.16 | 354,870 | |
| $21.52 | +1.10 | +5.4% | $20.45 | $21.59 | $20.05 | 523,033 | |
| $20.42 | -0.03 | -0.1% | $20.76 | $21.00 | $20.31 | 790,339 | |
| $20.45 | -0.42 | -2.0% | $20.85 | $20.85 | $20.09 | 520,381 | |
| $20.87 | +0.27 | +1.3% | $20.58 | $21.28 | $20.22 | 826,147 | |
| $20.60 | +0.13 | +0.6% | $20.52 | $20.99 | $20.13 | 724,341 | |
| $20.47 | +1.13 | +5.8% | $19.42 | $20.58 | $19.35 | 607,591 | |
| $19.34 | +0.82 | +4.4% | $18.75 | $19.49 | $18.49 | 871,846 | |
| $18.52 | -0.52 | -2.7% | $19.09 | $19.09 | $18.26 | 648,973 | |
| $19.04 | +0.34 | +1.8% | $18.86 | $19.30 | $18.76 | 418,028 | |
| $18.70 | +0.14 | +0.8% | $18.44 | $18.83 | $18.25 | 483,997 | |
| $18.56 | -1.04 | -5.3% | $19.39 | $19.60 | $18.54 | 469,540 | |
| $19.60 | -0.34 | -1.7% | $19.73 | $20.03 | $19.51 | 334,413 | |
| $19.94 | -0.03 | -0.2% | $19.93 | $20.59 | $19.73 | 649,439 | |
| $19.97 | -0.42 | -2.1% | $20.12 | $20.17 | $19.50 | 792,255 | |
| $20.39 | +0.15 | +0.7% | $19.97 | $20.79 | $19.80 | 477,743 | |
| $20.24 | -0.69 | -3.3% | $20.93 | $20.99 | $19.60 | 763,383 | |
| $20.93 | +0.50 | +2.4% | $20.57 | $21.03 | $19.94 | 614,360 | |
| $20.43 | -0.58 | -2.8% | $21.25 | $21.39 | $20.17 | 1,047,667 | |
| $21.01 | -0.86 | -3.9% | $21.78 | $22.32 | $20.88 | 889,699 | |
| $21.87 | -0.11 | -0.5% | $22.19 | $22.45 | $21.70 | 1,034,684 | |
| $21.98 | +0.53 | +2.5% | $21.37 | $22.62 | $21.29 | 501,797 | |
| $21.45 | -0.31 | -1.4% | $21.57 | $21.93 | $21.00 | 824,582 | |
| $21.76 | -0.65 | -2.9% | $22.33 | $22.41 | $21.67 | 1,421,983 | |
| $22.41 | -0.82 | -3.5% | $23.17 | $23.41 | $22.12 | 1,090,085 | |
| $23.23 | -2.34 | -9.2% | $25.27 | $25.39 | $22.86 | 1,102,779 | |
| $25.57 | -0.08 | -0.3% | $25.77 | $26.43 | $25.20 | 1,215,889 | |
| $25.65 | -0.08 | -0.3% | $26.04 | $26.96 | $25.40 | 989,217 | |
| $25.73 | +1.30 | +5.3% | $24.58 | $25.88 | $24.40 | 2,069,688 | |
| $24.43 | +0.08 | +0.3% | $24.80 | $25.17 | $24.27 | 511,825 | |
| $24.35 | -1.08 | -4.2% | $25.58 | $26.15 | $24.15 | 1,138,620 | |
| $25.43 | +0.36 | +1.4% | $24.71 | $25.78 | $24.15 | 1,142,331 | |
| $25.07 | +3.04 | +13.8% | $23.20 | $26.36 | $23.20 | 2,066,103 | |
| $22.03 | -1.51 | -6.4% | $23.63 | $23.96 | $21.86 | 1,548,636 | |
| $23.54 | +1.53 | +7.0% | $21.41 | $23.64 | $21.27 | 2,477,607 | |
| $22.01 | -4.72 | -17.7% | $18.94 | $22.30 | $18.66 | 6,069,061 | |
| $26.73 | -1.92 | -6.7% | $27.95 | $29.49 | $26.70 | 1,158,785 | |
| $28.65 | +3.79 | +15.2% | $24.51 | $29.56 | $24.51 | 1,864,601 | |
| $24.86 | -0.27 | -1.1% | $25.22 | $25.59 | $24.61 | 603,551 | |
| $25.13 | -0.17 | -0.7% | $25.52 | $26.42 | $24.80 | 567,917 | |
| $25.30 | +0.27 | +1.1% | $24.99 | $25.59 | $24.84 | 423,512 | |
| $25.03 | +0.09 | +0.4% | $24.82 | $25.21 | $24.17 | 423,798 | |
| $24.94 | -1.19 | -4.6% | $25.88 | $25.88 | $24.91 | 217,500 | |
| $26.13 | -0.09 | -0.3% | $26.17 | $26.69 | $25.92 | 253,994 | |
| $26.22 | -0.47 | -1.8% | $26.63 | $26.79 | $26.03 | 286,933 | |
| $26.69 | +0.60 | +2.3% | $26.47 | $26.99 | $26.30 | 317,813 | |
| $26.09 | +0.04 | +0.2% | $25.99 | $26.42 | $25.18 | 321,120 | |
| $26.05 | +0.36 | +1.4% | $25.95 | $26.81 | $25.95 | 493,596 | |
| $25.69 | -1.12 | -4.2% | $26.36 | $26.36 | $25.08 | 324,478 |
- Ticker
- NASDAQ:TYRA
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 10, 2026
Tyra Biosciences Reports Third Quarter 2026 Financial Results and Recent Highlights
Latest deck · September 2026
Investor Presentation (September 2026)
Investor deck · 47 slides
Latest news
Tyra Biosciences Reports Third Quarter 2026 Financial Results and Recent Highlights
Nov 10, 2026
Closed $21.00 (-5.8%) on Nov 10, 2026
Tyra Biosciences to Participate in Upcoming Investor Conferences
Nov 5, 2026
Closed $21.15 (+1.2%) on Nov 6, 2026
Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Sep 14, 2026
Closed $25.07 (+13.8%) on Sep 14, 2026
Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib
Sep 9, 2026
Closed $22.01 (-17.7%) on Sep 9, 2026
Tyra Biosciences to Present at the Cantor Global Healthcare Conference
Sep 8, 2026
Closed $22.01 (-17.7%) on Sep 9, 2026
Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026
Sep 4, 2026
Closed $28.65 (+15.2%) on Sep 4, 2026
Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights
Aug 4, 2026
Closed $25.71 (-21.0%) on Aug 5, 2026
TYRA Biosciences and BCAN establish May 21 as upper tract urothelial cancer (UTUC) awareness day
May 21, 2026
Closed $33.02 (-1.1%) on May 21, 2026
Tyra Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights
May 13, 2026
Closed $36.19 (+3.8%) on May 13, 2026
Tyra Biosciences Announces Appointment of Habib Dable to its Board of Directors
Apr 17, 2026
Closed $35.56 (+1.3%) on Apr 17, 2026
Tyra Biosciences, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 13 in the last 12 months · 67 in all · newest Nov 10, 2026 · oldest 2021
- Decks
- 3 decks · latest September 2026
Where Tyra Biosciences, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:TYRA · Home listing · This page | NASDAQ | United States | USD |
| BOATS:TYRA | BOATS | United States | USD |
Valuation
Price/book 2.0× against a median of 2.9×: 3rd lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $694.9M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 2.0×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 0.40
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Tyra Biosciences, Inc. · NASDAQ:TYRA | US$1.39B | US$694.9M | n/a | n/a | n/a | 2.0× | n/a | 0.0× | 0.40 |
| Sarepta Therapeutics, Inc. · NASDAQ:SRPT | US$1.43B | US$1.41B | n/a | 0.7× | n/a | 0.9× | −5.9% | 0.6× | 1.70 |
| ADARx Pharmaceuticals, Inc. · NASDAQ:ADRX | US$1.42B | US$521.8M | n/a | 77.6× | n/a | 2.5× | n/a | 0.0× | n/a |
| Nurix Therapeutics, Inc. · NASDAQ:NRIX | US$1.40B | US$683.6M | 4.8× | 1.0× | n/a | 1.4× | 42.0% | 0.0× | 1.15 |
| Intellia Therapeutics, Inc. · NASDAQ:NTLA | US$1.40B | US$1.00B | n/a | 19.0× | n/a | 2.3× | −805.7% | 0.1× | 2.01 |
| Wuhan Healthgen Biotechnology Corp Class A · SSE:688765 | US$1.37B | US$1.37B | n/a | 164× | n/a | 3.3× | −252.8% | 0.1× | n/a |
| Rapport Therapeutics, Inc. · NASDAQ:RAPP | US$1.37B | US$987.3M | n/a | 49.4× | n/a | 3.5× | −752.4% | 0.0× | 1.16 |
| Immunocore Holdings plc · NASDAQ:IMCR | US$1.36B | US$463.6M | n/a | 1.1× | n/a | 3.3× | −7.5% | 0.0× | 0.62 |
| Nanobiotix SA · EURONEXT:NANO | US$1.36B | US$1.36B | n/a | 41.7× | n/a | n/a | −80.8% | n/a | n/a |
| uniQure N.V. · NASDAQ:QURE | US$1.36B | US$739.1M | n/a | 36.6× | n/a | 4.6× | n/a | 0.2× | 1.25 |
| UroGen Pharma Ltd. · NASDAQ:URGN | US$1.36B | US$1.46B | n/a | 5.8× | n/a | n/a | −26.3% | n/a | 1.23 |
| Median of the others | US$1.37B | US$995.2M | 4.8× | 27.8× | 2.9× | −53.5% | 0.1× | 1.23 |
Forecasts
12 strong buy · 2 buy · 1 hold · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 47.45 USD · Analysts' mean
- EPS, year to Dec 2026
- -2.69 · 13 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Todd Harris | Chief Executive Officer |
| Alan Fuhrman | Chief Financial Officer |
| Bhavesh Ashar | Chief Operating Officer |
| Ali Fawaz | General Counsel and Secretary |
| Jonathan Day | EVP, Clinical Development |
| Sarah Honig | SVP, Corporate Development & Strategy |
| Daniel Bensen | Chief Discovery Officer |
| Doug Warner | Chief Medical Officer |
| Heather Faulds | Chief Regulatory Officer |
| Liz Pagano | Chief Human Resources Officer |
| Piyush Patel | Chief Development Officer |
| Robert L. Hudkins | Chief Technology Officer |
| Ronald V. Swanson | Chief Scientific Officer |
Board
| Director | Role |
|---|---|
| Adele Gulfo | Board Member |
| Habib Dable | Board Member |
| Jake Simson | Board Member |
| Melissa McCracken | Board Member |
| Rehan Verjee | Board Member |
| Robert More | Board Member |
| S. Michael Rothenberg | Board Member |
| Susan Moran | Board member |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 10, 2026 · Before open | −5.8% |
| Q2 2026 | Aug 4, 2026 · After close | −21.0% |
| Q1 2026 | Apr 30, 2026 | +0.8% |
| Q4 2025 | Mar 2, 2026 · After close | +1.5% |
| Q3 2025 | Nov 5, 2025 · After close | −3.6% |
| Q2 2025 | Aug 14, 2025 · After close | +0.3% |
| Q1 2025 | May 8, 2025 · After close | +0.2% |
| Q4 2024 | Mar 27, 2025 | −4.6% |
| Q3 2024 | Nov 7, 2024 · After close | −6.1% |
| Q2 2024 | Aug 7, 2024 · After close | +4.3% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 9, 2024 · After close | −2.3% |
| Q4 2023 | Mar 19, 2024 · After close | +7.9% |
| Q3 2023 | Nov 7, 2023 · After close | −1.3% |
| Q2 2023 | Aug 10, 2023 · After close | +1.9% |
| Q1 2023 | May 4, 2023 · After close | −2.8% |
| Q4 2022 | Mar 22, 2023 · After close | +1.9% |
| Q3 2022 | Nov 3, 2022 · After close | −0.1% |
| Q2 2022 | Aug 4, 2022 · After close | +15.0% |
| Q1 2022 | May 5, 2022 · After close | +4.9% |
| Q4 2021 | Mar 3, 2022 · After close | −1.5% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2026) | Investor deck | 47 slides | September 2026 |
| Corporate Update (October 2024) | Corporate update | 38 slides | Oct 25, 2024 |
| ENA Symposium (Abstract 500 LBA) | Conference | 23 slides |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock and pre-funded warrants Announced: about US$400M · US$22.03 a share · Jefferies +7 Dealers: Jefferies (co-lead), Guggenheim Securities (co-lead), Cantor (co-lead), Barclays (co-lead), William Blair (co-lead), Wedbush PacGrow, Raymond James, Oppenheimer & Co. Buyers: RA Capital Management (led the offering); Invus; Commodore Capital; BVF Partners; Janus Henderson Investors; Trails Edge Capital Partners; Integral Health Asset Management; TCGX; StemPoint Capital LP Use of proceeds: Advance dabogratinib development in LG-UTUC, IR NMIBC and achondroplasia, preclinical and discovery programs, working capital and general corporate purposes | Sep 14, 2026 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$16.00 a share on Sep 14, 2021.
- Price
- US$16.00 a share
- Shares offered
- 10,800,000 shares of common stock
- Offering size
- US$172.8 million
- Underwriters' option
- Up to 1,620,000 more shares
- Underwriters
- BofA Securities, Jefferies, Cowen · In the order on the cover
- Shares delivered
- On or about Sep 17, 2021
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | May 28, 2021 |
| Filed publicly | Aug 20, 2021 |
| Amended twice | Newest Sep 14, 2021 |
| Shares registered with an exchange | Sep 10, 2021 |
| Declared effective by the SEC | Sep 14, 2021 |
| Final prospectus, with the price | Sep 15, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Sep 15, 2021 |
| EFFECT · Notice that a registration is effective | Sep 14, 2021 |
| S-1MEF · Registration of more shares for the same offering | Sep 14, 2021 |
| S-1/A · Registration statement, amended | Sep 14, 2021 |
| CERT · Exchange's certificate of listing | Sep 13, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Sep 10, 2021 |
| CORRESP · Letter to the SEC | Sep 10, 2021 |
| CORRESP · Letter to the SEC | Sep 10, 2021 |
| S-1/A · Registration statement, amended | Sep 9, 2021 |
| CORRESP · Letter to the SEC | Aug 20, 2021 |
All 17 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Aug 20, 2021 |
| S-1 · Registration statement | Aug 20, 2021 |
| UPLOAD · Letter from the SEC | Jul 13, 2021 |
| DRSLTR · Letter to the SEC with a draft | Jul 2, 2021 |
| DRS/A · Draft registration statement, amended | Jul 2, 2021 |
| UPLOAD · Letter from the SEC | Jun 25, 2021 |
| DRS · Draft registration statement | May 28, 2021 |
Open IPO · From the cover of the final prospectus (424B4) filed Sep 15, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 546.0K | 519.0K | 353.0K | 296.0K | 140.0K | 47.0K | 8.00K |
| Gross profit | -546.0K | -519.0K | -353.0K | -296.0K | -140.0K | -47.0K | -8.00K |
| Research and development | 102.9M | 80.1M | 62.5M | 43.0M | 20.6M | 7.20M | 1.79M |
| Selling, general and administrative | 29.8M | 24.1M | 17.4M | 15.9M | 5.65M | 2.09M | 1.33M |
| Operating income | -132.8M | -104.2M | -79.9M | -58.9M | -26.3M | -9.30M | -3.12M |
| Depreciation and amortization | 546.0K | 519.0K | 357.0K | 296.0K | 140.0K | 47.0K | 8.00K |
| EBITDA | -132.2M | -103.7M | -79.6M | -58.6M | -26.1M | -9.25M | -3.11M |
| Interest expense | 296.0K | 140.0K | 1.00K | 1.00K | |||
| Income before tax | -119.9M | -86.5M | -69.1M | -55.3M | -26.3M | -9.34M | -4.07M |
| Income tax | 0 | 0 | 0 | 2.00K | 1.00K | 1.00K | -7.00K |
| Net income | -119.9M | -86.5M | -69.1M | -55.3M | -26.3M | -9.34M | -4.06M |
| Earnings per share, basic | -2.01 | -1.51 | -1.62 | -1.32 | -1.91 | -6.05 | -0.10 |
| Earnings per share, diluted | -2.01 | -1.51 | -1.62 | -1.32 | -1.91 | -6.05 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 77.4M | 92.0M | 58.0M | 251.2M | 302.2M | 15.2M | 108.0K |
| Short-term investments | 178.6M | 249.5M | 145.5M | 0 | |||
| Receivables | 2.00M | 700.0K | |||||
| Current assets | 265.4M | 347.5M | 211.7M | 257.3M | 304.1M | 15.3M | 127.0K |
| Property, plant and equipment | 1.31M | 1.65M | 1.63M | 1.08M | 1.03M | 297.0K | 276.0K |
| Total assets | 282.6M | 363.6M | 225.9M | 266.2M | 306.7M | 16.0M | 528.0K |
| Accounts payable | 1.18M | 590.0K | 4.66M | 1.15M | 599.0K | 664.0K | 327.0K |
| Current liabilities | 18.1M | 14.6M | 15.3M | 5.70M | 3.62M | 1.86M | 5.16M |
| Total debt | 5.81M | 6.22M | 6.50M | 2.62M | 1.18M | 142.0K | 253.0K |
| Total liabilities | 23.4M | 20.4M | 21.6M | 8.35M | 4.96M | 2.00M | 5.27M |
| Shareholders' equity | 259.2M | 343.2M | 204.3M | 257.8M | 301.7M | -13.6M | -4.74M |
| Shares outstanding | 53.7M | 50.7M | 43.0M | 42.4M | 41.4M | 1.83M | 42.5M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -95.1M | -69.8M | -50.1M | -50.3M | -23.7M | -7.76M | -2.62M |
| Capital spending | -141.0K | -664.0K | -770.0K | -559.0K | -661.0K | -312.0K | -20.0K |
| Free cash flow | -95.3M | -70.4M | -50.9M | -50.8M | -24.4M | -8.07M | -2.64M |
| Cash from investing | 72.5M | -98.4M | -144.6M | -559.0K | -645.0K | -312.0K | -20.0K |
| Cash from financing | 8.10M | 202.1M | 1.54M | 632.0K | 311.3M | 23.4M | 157.0K |
| Share buybacks | 0 | -420.0K | 0 | 311.4M | |||
| Change in cash | -14.6M | 34.0M | -193.2M | -50.2M | 287.0M | 15.4M | -2.48M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 10, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 27, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Sep 21, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 17, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Sep 17, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 17, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Sep 17, 2026 | Big-stake notice | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Sep 14, 2026 | Current report | SEC |
| 424B5 · Prospectus | Sep 14, 2026 | Offer document | SEC |
| FWP · Free writing prospectus | Sep 14, 2026 | Offer document | SEC |
| S-3ASR · Registration statement | Sep 14, 2026 | Offer document | SEC |
| 4 · Change in ownership | Sep 11, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 9, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 424B5 · Prospectus | Aug 4, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 4, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 4, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 30, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Jun 26, 2026 | Other filings | SEC |
| 8-K · Current report | Jun 2, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 1, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2026 | Results | SEC |
| 144 · Notice of proposed sale | May 12, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 12, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | May 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 7, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 24, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 20, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 20, 2026 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 17, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 17, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 17, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 17, 2026 | Management or board change | SEC |
| 144 · Notice of proposed sale | Apr 13, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 7, 2026 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Apr 2, 2026 | Insider trade | SEC |
| 8-K · Current report | Apr 2, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Mar 27, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 26, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 25, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 12, 2026 | Other filings | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 6, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Mar 4, 2026 | Current report | SEC |
| 10-K · Annual report | Mar 2, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 2, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 20, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 13, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 13, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Feb 12, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 20, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 12, 2026 | Other filings | SEC |
| 4 · Change in ownership | Dec 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 16, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 12, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 1, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 1, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 1, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Nov 25, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 21, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 19, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 18, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 17, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 17, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Nov 14, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Nov 13, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 5, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2025 | Results | SEC |
| 4 · Change in ownership | Sep 17, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 21, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Aug 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 7, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 7, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 30, 2025 | Current report | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 18, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 17, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 16, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 13, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 12, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jun 11, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jun 6, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 8-K · Current report | May 29, 2025 | Meeting outcome | SEC |
| EFFECT · Notice that a registration is effective | May 19, 2025 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 14, 2025 | Big-stake notice | SEC |
| CORRESP · Letter to the SEC | May 14, 2025 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | May 14, 2025 | Big-stake notice | SEC |
| UPLOAD · Letter from the SEC | May 12, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 12, 2025 | Big-stake notice | SEC |
| S-3 · Registration statement | May 8, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | May 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2025 | Results | SEC |
| ARS · Annual report to shareholders | Apr 18, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 18, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 18, 2025 | Meeting notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 31, 2025 | Big-stake notice | SEC |
| 10-K · Annual report | Mar 27, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 27, 2025 | Results | SEC |
| 4 · Change in ownership | Mar 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Mar 6, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 7, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Feb 5, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 5, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jan 31, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 31, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 29, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Jan 27, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 22, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jan 21, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 21, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Dec 9, 2024 | Other filings | SEC |
| SC 13D/A · Big-stake notice, amended | Dec 6, 2024 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Dec 5, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 2, 2024 | Other filings | SEC |
| 4 · Change in ownership | Nov 26, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 20, 2024 | Other filings | SEC |
| SC 13D/A · Big-stake notice, amended | Nov 19, 2024 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Nov 14, 2024 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | Nov 13, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 13, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 8, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 7, 2024 | Results | SEC |
| 4 · Change in ownership | Nov 6, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 1, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 30, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 30, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 28, 2024 | Other filings | SEC |
| 8-K · Current report | Oct 28, 2024 | Current report | SEC |
| 8-K · Current report | Oct 25, 2024 | Management or board change | SEC |
| SC 13D/A · Big-stake notice, amended | Oct 22, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 22, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 22, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Oct 22, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 22, 2024 | Insider trade | SEC |
| 8-K · Current report | Oct 18, 2024 | Financing | SEC |
| 4 · Change in ownership | Oct 17, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 16, 2024 | Other filings | SEC |
| SC 13D/A · Big-stake notice, amended | Oct 15, 2024 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | Oct 15, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 20, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 20, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 18, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 18, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 18, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 18, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 18, 2024 | Other filings | SEC |
| 4 · Change in ownership | Sep 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 10, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 16, 2024 | Insider trade | SEC |
This page holds 200 of 428 filings. Open Filings
Cap table
Built by 6ix from Tyra Biosciences, Inc.’s releases · as of Nov 6, 2026
- Common shares
- 69,082,747
- Fully diluted
- 69,082,747
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 69,082,747 | Nov 6, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 6, 2026 | 69,082,747 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Rajeev M Shah Other companies: Freenome, Inc. (Director · Since at least Jul 20, 2026); Parabilis Medicines, Inc. (Director · Since at least Jun 9, 2026); Hemab Therapeutics Holdings, Inc. (Director · Since at least Apr 30, 2026); SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Evommune, Inc. (Director · Since at least Nov 5, 2025); Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Septerna, Inc. (Director · Since at least Oct 24, 2024); Bicara Therapeutics Inc. (Director · Since at least Sep 12, 2024); Artiva Biotherapeutics, Inc. (Director · Since at least Jul 18, 2024); Cidara Therapeutics Inc (Director · Since at least Apr 24, 2024); LENZ Therapeutics, Inc. (Director · Since at least Mar 21, 2024); Mineralys Therapeutics, Inc. (Director · Since at least Feb 9, 2023); Acrivon Therapeutics, Inc. (Director · Since at least Nov 9, 2022); ARS Pharmaceuticals, Inc. (Director · Since at least Nov 8, 2022); PepGen Inc. (Director · Since at least May 5, 2022); Nkarta, Inc. (Director · Since at least Feb 14, 2022); Wave Life Sciences Ltd. (Director · Since at least Aug 16, 2021); Climb Bio, Inc. (Director · Since at least Aug 9, 2021); Acumen Pharmaceuticals, Inc. (Director · Since at least Jun 30, 2021); Janux Therapeutics, Inc. (Director · Since at least Jun 10, 2021); Vor Biopharma Inc. (Director · Since at least Feb 4, 2021); 89bio Inc (Director · Since at least Nov 8, 2019); Iteos Therapeutics Inc (Director · Jun 9, 2022 – Jun 9, 2022 · Past); Forma Therapeutics Holdings Inc (Director · Jun 8, 2022 – Jun 8, 2022 · Past); Icosavax Inc (Director · Jul 28, 2021 – Feb 19, 2024 · Past); Cytek Biosciences, Inc. (Director · Jul 22, 2021 – Mar 14, 2022 · Past); Jade Biosciences, Inc. (Director · Jun 29, 2021 – Jun 17, 2024 · Past); POINT Biopharma Global Inc (Director · Jun 23, 2021 – Jun 29, 2021 · Past); Werewolf Therapeutics, Inc. (Director · Apr 29, 2021 – May 12, 2025 · Past); Orchard Therapeutics PLC (Director · Feb 9, 2021 – Feb 9, 2021 · Past); Black Diamond Therapeutics, Inc. (Director · Jan 29, 2020 – Jul 5, 2023 · Past); Satsuma Pharmaceuticals Inc (Director · Sep 12, 2019 – Jun 6, 2023 · Past); Eidos Therapeutics Inc (Director · Jun 19, 2018 – May 27, 2020 · Past); Solid Biosciences Inc. (Director · Jan 25, 2018 – Jan 11, 2024 · Past); Kala Bio, Inc. (Director · Jul 19, 2017 – Jun 17, 2021 · Past); KalVista Pharmaceuticals, Inc. (Director · Nov 21, 2016 – Oct 12, 2017 · Past); Ra Pharmaceuticals Inc (Director · Oct 25, 2016 – Apr 2, 2020 · Past) | Director · Since at least Sep 14, 2021 |
| Habib Joseph Dable Other companies: SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Relay Therapeutics, Inc. (Director · Since at least Nov 4, 2025); Day One Biopharmaceuticals Inc (Director · Since at least Jan 17, 2024); PepGen Inc. (Director · Since at least Sep 20, 2022); Blueprint Medicines Corp (Director · Since at least Jun 23, 2022); Jade Biosciences, Inc. (Director · Jul 10, 2023 – Jun 5, 2024 · Past); Albireo Pharma Inc (Director · Aug 8, 2022 – Mar 2, 2023 · Past); Acceleron Pharma Inc (CEO and President, Director · Jan 4, 2021 – Nov 19, 2021 · Past) | Director · Since at least Apr 16, 2026 |
| Adele M. Gulfo Other companies: NewAmsterdam Pharma Company N.V. (Director · Since at least Apr 15, 2025); Enpro Inc. (Director · Since at least Oct 30, 2018); Myovant Sciences Ltd (Director · Dec 27, 2019 – Mar 10, 2023 · Past); Bemis Company Inc (Director · Jun 23, 2015 – Jun 11, 2019 · Past) | Board Member · Since at least Jan 29, 2025 |
| Susan Moran Other companies: Crescent Biopharma, Inc. (Director · Since at least Jun 13, 2025); BioAtla, Inc. (Director · Since at least Dec 15, 2020); RayzeBio, Inc. (CHIEF MEDICAL OFFICER · Sep 14, 2023 – Feb 26, 2024 · Past) | Board member · Since at least May 7, 2024 |
| Gilla Kaplan Other companies: Avalo Therapeutics, Inc. (Director · Since at least Oct 8, 2020); Celgene Corporation (Director · Oct 30, 2006 – May 18, 2018 · Past) | Director · Since at least Sep 14, 2021 |
| Robert More Other companies: Vir Biotechnology, Inc. (Director · Since at least Oct 10, 2019); Glaukos Corporation (Director · Jun 24, 2015 – Jun 30, 2015 · Past) | Board Member · Since at least Sep 14, 2021 |
| Alan Fuhrman Other companies: SpringWorks Therapeutics Inc (Director · Since at least May 14, 2025) | Chief Financial Officer · Since at least Aug 7, 2025 |
| Bhavesh Ashar Other companies: SpringWorks Therapeutics Inc (Chief Commercial Officer · Since at least Mar 22, 2021) | Chief Operating Officer · Since at least Dec 1, 2025 |
| Douglas J Warner Other companies: eFFECTOR Therapeutics Inc (Chief Medical Officer · Aug 8, 2022 – Feb 19, 2024 · Past) | Chief Medical Officer · Since at least Sep 9, 2024 |
| John Stephen Healy Other companies: Contineum Therapeutics, Inc. (General Counsel and Corp Sec · Since at least May 30, 2024) | General Counsel and Secretary · Mar 1, 2022 – Mar 1, 2022 · Past |
All 29 people
| Person | Seat |
|---|---|
| Ali Fawaz | General Counsel and Secretary · Since at least May 16, 2022 |
| Daniel Bensen | Chief Discovery Officer · Since at least Feb 2, 2024 |
| Doug Warner | Chief Medical Officer · Since at least Nov 7, 2024 |
| Heather Faulds | Chief Regulatory Officer · Since at least Dec 1, 2025 |
| Isan Chen | Director · Sep 14, 2021 – May 31, 2023 · Past |
| Jake Simson | Board Member · Since at least Nov 4, 2026 |
| Jonathan Day | EVP, Clinical Development · Since at least Aug 4, 2026 |
| Liz Pagano | Chief Human Resources Officer · Since at least Nov 4, 2026 |
| Melissa McCracken | Board Member · Since at least Sep 14, 2021 |
| Piyush Patel | Chief Development Officer · Since at least Sep 14, 2021 |
| Rehan Verjee | Board Member · Since at least Sep 14, 2021 |
| Robert L. Hudkins | Chief Technology Officer · Since at least Nov 5, 2026 |
| Ronald V. Swanson | Chief Scientific Officer · Since at least Sep 14, 2021 |
| Sarah Honig | SVP, Corporate Development & Strategy · Since at least Nov 4, 2026 |
| Siddarth Subramony | Director · Sep 14, 2021 – May 29, 2024 · Past |
| S. Michael Rothenberg | Board Member · Since at least Nov 5, 2026 |
| Stephen Michael Rothenberg | Director · Since at least May 29, 2025 |
| Todd Harris | Chief Executive Officer · Since at least May 5, 2026 |
| Yuliya Rueb | Vice President, Finance (PAO) · Since at least Apr 1, 2026 |
Log in to ask 6ix AI your own questions about Tyra Biosciences, Inc.